Trial Profile
A Phase II Study to Evaluate Foretinib in Genomic Subpopulations of Subjects With Non-Small-Cell Lung Cancer (NSCLC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Foretinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 20 Sep 2014 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center:9L13-8)
- 20 Sep 2014 New source identified and integrated (M.D. Anderson Cancer Center:2013-1012)
- 15 May 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.